-
Mashup Score: 5Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC - 2 day(s) ago
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3SNB-101 Receives FDA Fast Track Designation for SCLC - 2 day(s) ago
SNB-101 has received FDA fast track designation for potential use in patients with small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - 14 day(s) ago
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - 17 day(s) ago
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - 24 day(s) ago
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial - 29 day(s) ago
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination’s use in patients with non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Consolidation Durvalumab Generates Survival Benefit in LS-SCLC - 29 day(s) ago
Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC #lcsm #oncology https://t.co/YSOoeOPcY9